In gliomas, GPR65 serves as the primary lactate receptor on TAMs, where it activates the cAMP/PKA/CREB pathway, induces high mobility group box 1 (HMGB1) secretion, and fosters glioma progression. Here, CREB1 is linked to central nervous system cancer.